Swedish study shows precision medicine improves treatment of metastatic castration-resistant prostate cancer using genetic profiling.

A Swedish study shows precision medicine improves treatment of metastatic castration-resistant prostate cancer by using genetic profiling to determine the effectiveness of second-generation hormone drugs. The ProBio study, published in Nature Medicine, reveals patients with specific tumor mutations respond better to Androgen Receptor Pathway inhibitors (ARPi), which have longer life expectancy than chemotherapy. This research suggests that precision medicine can improve treatment for men with metastatic prostate cancer.

August 20, 2024
4 Articles

Further Reading